3 results
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in patients with gMG on stable background therapy. In addition, the study will assess the long-term safety and efficacy of…
The primary objective of the ADFICE_IT study is to investigate the effects of a CDSS and patient portal for optimizing FRID withdrawal on injurious falls. This study has three secondary objectives. First, we will investigate the effect of the CDSS…